IRLAB Therapeutics Balance Sheet Health
Financial Health criteria checks 3/6
IRLAB Therapeutics has a total shareholder equity of SEK38.0M and total debt of SEK52.5M, which brings its debt-to-equity ratio to 138%. Its total assets and total liabilities are SEK160.3M and SEK122.3M respectively.
Key information
138.0%
Debt to equity ratio
SEK 52.47m
Debt
| Interest coverage ratio | n/a |
| Cash | SEK 90.38m |
| Equity | SEK 38.03m |
| Total liabilities | SEK 122.26m |
| Total assets | SEK 160.29m |
Recent financial health updates
Is IRLAB Therapeutics (STO:IRLAB A) Using Debt Sensibly?
Oct 30
IRLAB Therapeutics (STO:IRLAB A) Has Debt But No Earnings; Should You Worry?
Jun 06Here's Why We're Watching IRLAB Therapeutics' (STO:IRLAB A) Cash Burn Situation
Jan 04Here's Why IRLAB Therapeutics (STO:IRLAB A) Must Use Its Cash Wisely
Sep 21We Think IRLAB Therapeutics (STO:IRLAB A) Needs To Drive Business Growth Carefully
Mar 18IRLAB Therapeutics (STO:IRLAB A) Is In A Good Position To Deliver On Growth Plans
Dec 01Recent updates
Is IRLAB Therapeutics (STO:IRLAB A) Using Debt Sensibly?
Oct 30IRLAB Therapeutics (STO:IRLAB A) Has Debt But No Earnings; Should You Worry?
Jun 06Here's Why We're Watching IRLAB Therapeutics' (STO:IRLAB A) Cash Burn Situation
Jan 04Here's Why IRLAB Therapeutics (STO:IRLAB A) Must Use Its Cash Wisely
Sep 21We Think IRLAB Therapeutics (STO:IRLAB A) Needs To Drive Business Growth Carefully
Mar 18IRLAB Therapeutics (STO:IRLAB A) Is In A Good Position To Deliver On Growth Plans
Dec 01We Like IRLAB Therapeutics' (STO:IRLAB A) Earnings For More Than Just Statutory Profit
May 19We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow
Sep 11We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow
Apr 30What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?
Mar 19We Think IRLAB Therapeutics (STO:IRLAB A) Can Afford To Drive Business Growth
Jan 25Our View On IRLAB Therapeutics' (STO:IRLAB A) CEO Pay
Dec 21What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?
Nov 25
Financial Position Analysis
Short Term Liabilities: IRLAB A's short term assets (SEK102.5M) do not cover its short term liabilities (SEK117.9M).
Long Term Liabilities: IRLAB A's short term assets (SEK102.5M) exceed its long term liabilities (SEK4.4M).
Debt to Equity History and Analysis
Debt Level: IRLAB A has more cash than its total debt.
Reducing Debt: IRLAB A's debt to equity ratio has increased from 0% to 138% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IRLAB A has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if IRLAB A has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.